Oppenheimer Maintains Outperform on Kyntra Bio, Lowers Price Target to $30

Benzinga · 1d ago
Oppenheimer analyst Jay Olson maintains Kyntra Bio (NASDAQ:KYNB) with a Outperform and lowers the price target from $35 to $30.